Related Experiment Videos
Are diabetic metabolic compensation and CA19.9 really correlated?
G Banfi1, A Ardemagni, S Bravi
1Servizio Intergrato di Medicina di Laboratorio, Istituto Scientifico H San Raffaele, Milano, Italy.
The International Journal of Biological Markers
|October 1, 1996
Summary
This study found no correlation between CA19.9 levels and diabetes control markers like glycated hemoglobin. Therefore, CA19.9 should be interpreted similarly in diabetic and non-diabetic patients for pancreatic cancer screening.
Area of Science:
- Endocrinology
- Oncology
- Clinical Biochemistry
Background:
- Diabetes mellitus is a complex metabolic disorder.
- Pancreatic cancer is a serious malignancy with challenging diagnosis.
- The tumor marker CA19.9 has been investigated for its role in both conditions.
Purpose of the Study:
- To investigate the correlation between CA19.9 levels and glycemic control in diabetic patients.
- To determine if CA19.9 can serve as a marker for exocrine damage in diabetes.
- To assess the utility of CA19.9 in diabetic patients compared to non-diabetic individuals.
Main Methods:
- Studied 64 diabetic patients with varying insulin dependency and dietary management.
- Measured serum CA19.9 levels using two distinct immunometric assays.
- Assessed glycemic control through measurements of glycemia and glycated hemoglobin.
Main Results:
- No significant correlation was found between CA19.9 levels and markers of metabolic compensation in diabetes.
- No differences in CA19.9 concentrations were observed between insulin-dependent and non-insulin-dependent diabetic patients.
- The study indicated that CA19.9's association with metabolic control in diabetes is not a reliable indicator.
Conclusions:
- CA19.9 levels in diabetic patients do not correlate with glycemic control.
- CA19.9 should not be used as a specific marker for exocrine damage severity in diabetes.
- Interpretation of elevated CA19.9 in diabetic individuals should follow the same clinical guidelines as for non-diabetic patients.